Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aventis Ketek Recommended For Pneumonia, Sinusitis, And Bronchitis

Executive Summary

Aventis' Ketek should gain approval for the treatment of community-acquired pneumonia, acute exacerbations of chronic bronchitis and acute sinusitis, FDA's Anti-Infective Drugs Advisory Committee agreed Jan. 8

You may also be interested in...



Two Strikes For Ketek: Cmtes. Want Bronchitis, Sinusitis Indications Rescinded

FDA's Anti-Infective Drug and Drug Safety and Risk Management Advisory Committees are recommending stripping Sanofi-Aventis' Ketek of its bronchitis and sinusitis indications

Two Strikes For Ketek: Cmtes. Want Bronchitis, Sinusitis Indications Rescinded

FDA's Anti-Infective Drug and Drug Safety and Risk Management Advisory Committees are recommending stripping Sanofi-Aventis' Ketek of its bronchitis and sinusitis indications

Aventis Ketek July Launch Will Highlight Targeted Antibacterial Activity

Aventis' promotional message for Ketek will center on the antibiotic's ability to specifically target all pathogens commonly associated with respiratory tract infections without affecting other bacterial strains

Related Content

UsernamePublicRestriction

Register

OM017301

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel